The Role of Postoperative Antibiotics in Laparoscopic Cholecystectomy

NCT06607887 · tracked via the Priya Life Science Egypt tracker

Sponsor

Minia University Hospital

Phase

Phase 4

Started

2024-08-30

Last updated

2024-09-23

Condition(s) studied

Infection WoundAntibiotic Resistant Infection

Investigational drug(s) / intervention(s)

IV antibioticOral antibiotic

IV antibiotic: Parenteral prophylactic antibiotics (cefazolin), 1st dose at the time of induction of anesthesia, 2nd dose after 12hs from the surgery.

Oral antibiotic: Parenteral prophylactic antibiotic (cefazolin), dose at the time of induction of anesthesia and then oral antibiotic for five days postoperative.

Study summary

Comparison between postoperative parenteral prophylactic antibiotics, and oral antibiotics regarding the incidence of post laparoscopic cholecystectomy infection.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Adult patients (aged above 18 years) undergoing laparoscopic cholecystectomy. Exclusion Criteria: * patients with comorbidities (Diabetes, malignancies, Immunosuppressed). Lost of follow-up. Patients received antibiotics within 72 hr before admission. Complicated cases involved, gangrenous and perforated cholecystitis and abscess.

Primary outcome measure(s)

Surgical site infection — 4 weeks
DSSI = deep surgical site infection; SSSI = superficial surgical site infection.

Trial sites (1)

Facility	City	Region	Status
Minia University Hospital	Minya	Egypt	Recruiting

More Minia University Hospital trials in Egypt

Hyaluronic Acid Injection in Idiopathic Carpal Tunnel Syndrome; is it Effective as Local Corticosteroids Starting soon

Spinal Analgesia in Labour Pain Starting soon

UBM Evaluation After Combined Deep Sclerectomy With Trabeculotomy in Primary Open Angle Glaucoma Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06607887 on ClinicalTrials.gov ↗ ← All trials in Egypt